General Information of Drug (ID: DMWTVAN)

Drug Name
RAUWOLFIA SERPENTINA ROOT
Synonyms
Raubasine; 483-04-5; Ajmalicin; Circolene; Sarpan; py-Tetrahydroserpentine; Tetrahydroserpentine; UNII-4QJL8OX71Z; EINECS 207-589-5; BRN 0097268; 4QJL8OX71Z; CHEBI:2524; CHEMBL123325; Methyl 16,17-didehydro-19alpha-methyl-18-oxayohimban-16-carboxylat; 16,17-Didehydro-19-methyloxayohimban-16-carboxylic acid m
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Approved [1]
Drug Type
Small molecular drug
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 2.098 +/- 0.441 mg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.042 +/- 0.80 h [2]
Bioavailability
The bioavailability of drug is 64% [2]
Clearance
The drug is cleared by the liver and kidneys [3]
Elimination
The elimination of reserpine and its metabolites in the feces ranges from 30% after intramuscular administration to about 60% after oral ingestion, primarily as unmetabolized reserpine, over a 4 day period after the ingestionof 0.25 mg to 0.50 mg doses [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 hours [4]
Metabolism
The drug is metabolized via the hepatic [5]
Cross-matching ID
UNII
H192N84N1G
DrugBank ID
DB09363
TTD ID
D0U7GP
VARIDT ID
DR01047

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) TTZIFHC CAC1C_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
2 Bolton GC, Allen GD, Davies BE, Filer CW, Jeffery DJ: The disposition of clavulanic acid in man. Xenobiotica. 1986 Sep;16(9):853-63. doi: 10.3109/00498258609038967.
3 Reserpine
4 Reserpine, Drugs.com
5 Reserpine